Indications and uses
This Homeopathic product of natural source helps relieve the discomfort and pain caused by hemorrhoids and fissures.
This Homeopathic product of natural source helps relieve the discomfort and pain caused by hemorrhoids and fissures.
Adults: Allow 3 pellets to dissolve under the tongue 3 times a day, or as directed by a health professional. For adult use only. Do not exceed recommended dosage.
Aesculus hippocastanum 1X
Hamamelis virginiana 1X
Paeonia officinalis 3X
Collinsonia 3X
Teucrium marum 3X
Verbascum thapsus 3X
Boldo 1X
Sulphur 4X
Sodium nitrate 3X
Ratanhia 3X
Acidum nitricum 8X
Natrum muriaticum 8X
Podophyllum peltatum 4X
Ruta graveolens 8X
Apis mellifica 4X
Manufactured according to the Homeopathic Pharmacopoeia of the United States (HPUS)
Helps relieve discomfort of hemorrhoids and fissures
This Homeopathic product of natural source helps relieve the discomfort and pain caused by hemorrhoids and fissures.
If symptoms persist or worsen, discontinue use and contact a health professional.
As with any drug, if you are pregnant or nursing a baby, seek the advice of a health professional before using this product.
Keep this and all medications out of reach of children.
Adults: Allow 3 pellets to dissolve under the tongue 3 times a day, or as directed by a health professional.
For adult use only. Do not exceed recommended dosage.
Do not use if cap seal is broken.
Homeolab USA Inc., 3025 De L'Assomption Blvd., Montreal, QC H1N 2H2 Canada
PRODUCT OF CANADA
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 60512-9059-1 | 2025-12-29 | C162847 | 48780-1 | 9d75b9d0-4fa5-f424-e053-dadaa90a57ce | DRUG FACTS |
| 60512-9059-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4fa5-f424-e053-dadaa90a57ce | DRUG FACTS |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60512-9059 | HEMORRHOIDS RELIEF (AESCULUS HIPPOCASTANUM, HAMAMELIS VIRGINIANA, PAEONIA OFFICINALIS, COLLINSONIA, TEUCRIUM MARUM, VERBASCUM, BOLDO, SULPHUR, SODIUM NITRATE, RATANHIA, ACIDUM NITRICUM, NATRUM MURIATICUM, PODOPHYLLUM PELTATUM, RUTA GRAVEOLENS, APIS MELLIFICA) PELLET [HOMEOLAB USA INC.] | 2 | Legacy NDC | 20140513_0025ae07-e4cb-4ab6-9717-2d172bc24b63.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| APIS MELLIFERA | ACTIVE INGREDIENT | 7S82P3R43Z | 2 | |
| COLLINSONIA CANADENSIS ROOT | ACTIVE INGREDIENT | O2630F3XDR | 2 | |
| HORSE CHESTNUT | ACTIVE INGREDIENT | 3C18L6RJAZ | 2 | |
| KRAMERIA LAPPACEA ROOT | ACTIVE INGREDIENT | P29ZH1A35Z | 2 | |
| NITRIC ACID | ACTIVE INGREDIENT | 411VRN1TV4 | 2 | |
| PAEONIA OFFICINALIS ROOT | ACTIVE INGREDIENT | 8R564U2E1P | 2 | |
| PEUMUS BOLDUS LEAF | ACTIVE INGREDIENT | Q4EWM09M3O | 2 | |
| PODOPHYLLUM PELTATUM ROOT | ACTIVE INGREDIENT | 2S713A4VP3 | 2 | |
| RUTA GRAVEOLENS FLOWERING TOP | ACTIVE INGREDIENT | N94C2U587S | 2 | |
| SODIUM CHLORIDE | ACTIVE INGREDIENT | 451W47IQ8X | 2 | |
| SODIUM NITRATE | ACTIVE INGREDIENT | 8M4L3H2ZVZ | 2 | |
| SULFUR | ACTIVE INGREDIENT | 70FD1KFU70 | 2 | |
| TEUCRIUM MARUM | ACTIVE INGREDIENT | 10464S0TAA | 2 | |
| VERBASCUM THAPSUS | ACTIVE INGREDIENT | C9TD27U172 | 2 | |
| WITCH HAZEL | ACTIVE INGREDIENT | 101I4J0U34 | 2 | |
| APIS MELLIFERA | ACTIVE MOIETY | 7S82P3R43Z | 2 | |
| CHLORIDE ION | ACTIVE MOIETY | Q32ZN48698 | 2 | |
| COLLINSONIA CANADENSIS ROOT | ACTIVE MOIETY | O2630F3XDR | 2 | |
| HORSE CHESTNUT | ACTIVE MOIETY | 3C18L6RJAZ | 2 | |
| KRAMERIA LAPPACEA ROOT | ACTIVE MOIETY | P29ZH1A35Z | 2 | |
| NITRATE ION | ACTIVE MOIETY | T93E9Y2844 | 2 | |
| NITRIC ACID | ACTIVE MOIETY | 411VRN1TV4 | 2 | |
| PAEONIA OFFICINALIS ROOT | ACTIVE MOIETY | 8R564U2E1P | 2 | |
| PEUMUS BOLDUS LEAF | ACTIVE MOIETY | Q4EWM09M3O | 2 | |
| PODOPHYLLUM | ACTIVE MOIETY | 2S713A4VP3 | 2 | |
| RUTA GRAVEOLENS FLOWERING TOP | ACTIVE MOIETY | N94C2U587S | 2 | |
| SULFUR | ACTIVE MOIETY | 70FD1KFU70 | 2 | |
| TEUCRIUM MARUM | ACTIVE MOIETY | 10464S0TAA | 2 | |
| VERBASCUM THAPSUS | ACTIVE MOIETY | C9TD27U172 | 2 | |
| WITCH HAZEL | ACTIVE MOIETY | 101I4J0U34 | 2 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 2 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 60512-9059 | 60512-9059-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| HORSE CHESTNUT | 3C18L6RJAZ | ACTIB |
| WITCH HAZEL | 101I4J0U34 | ACTIB |
| PAEONIA OFFICINALIS ROOT | 8R564U2E1P | ACTIB |
| COLLINSONIA CANADENSIS ROOT | O2630F3XDR | ACTIB |
| TEUCRIUM MARUM | 10464S0TAA | ACTIB |
| VERBASCUM THAPSUS | C9TD27U172 | ACTIB |
| PEUMUS BOLDUS LEAF | Q4EWM09M3O | ACTIB |
| SULFUR | 70FD1KFU70 | ACTIB |
| SODIUM NITRATE | 8M4L3H2ZVZ | ACTIB |
| KRAMERIA LAPPACEA ROOT | P29ZH1A35Z | ACTIB |
| NITRIC ACID | 411VRN1TV4 | ACTIB |
| SODIUM CHLORIDE | 451W47IQ8X | ACTIB |
| PODOPHYLLUM PELTATUM ROOT | 2S713A4VP3 | ACTIB |
| RUTA GRAVEOLENS FLOWERING TOP | N94C2U587S | ACTIB |
| APIS MELLIFERA | 7S82P3R43Z | ACTIB |
| SUCROSE | C151H8M554 | IACT |
| LACTOSE | J2B2A4N98G | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 4721fb64-bc1c-b450-e063-6294a90a056e | 0025ae07-e4cb-4ab6-9717-2d172bc24b63 | 2025-12-29 | Warnings | 0025ae07-e4cb-4ab6-9717-2d172bc24b63 |
Adverse event summaries are temporarily unavailable. Other product information remains available.